{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:50:06Z","timestamp":1794631806404,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To study the profile, clinical presentation and outcome of hospital stay among patients admitted with warfarin toxicity at the Jigme Dorji Wangchuck National Referral Hospital, Bhutan. This was a cross-sectional study with a review of hospital records of patients admitted between 01 and 2018 and 30 June 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 22 admissions due to warfarin toxicity. The mean age of patients was 55.9 (\u00b1\u2009SD 20.2) years, the median duration of warfarin therapy was 30 months (IQR 4.8, 69 months). The indications for warfarin were atrial fibrillation (9, 40.9%), mechanical heart valves (6, 27.3%), deep vein thrombosis (6, 27.3%) and pulmonary thromboembolism (1, 4.5%). The mean of dosage of warfarin was 4.3 (\u00b1\u20092.6) mg and the cumulative dosage in the week prior to admission was 30.9 (\u00b1\u200918.6) mg. The mean of INR at presentation was 7.7 (\u00b1\u20094.3) with the maximum noted at 20. The patients presented with gastrointestinal bleeding, muscle haematomas, epistaxis and oral cavity bleeding. There was no mortality related to warfarin toxicity. The reasons for warfarin toxicity included patient dosing error and drug interactions. Warfarin therapy requires appropriate patient education, adequate facilities for follow-up and avoidance of warfarin wherever possible in clinical settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-023-06359-2","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T11:03:43Z","timestamp":1684407823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Profile and outcome of patients with Warfarin Toxicity admitted in a tertiary care hospital in Bhutan: a cross-sectional study investigators and institutions"],"prefix":"10.1186","volume":"16","author":[{"given":"Yeshey","family":"Penjore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinley","family":"Dorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangay","family":"Dorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran Tenzin","family":"Tamang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"6359_CR1","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.16201","volume":"316","author":"N Shehab","year":"2016","unstructured":"Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department visits for outpatient adverse drug events, 2013\u20132014. JAMA. 2016;316:2115\u201325.","journal-title":"JAMA"},{"key":"6359_CR2","unstructured":"British National Formulary 77. March - September 2019. BMJ Group & Pharmaceutical Press; 2019."},{"key":"6359_CR3","volume-title":"Warfarin Therapy and VKORC1 and CYP genotype. Medical Genetics Summaries","author":"L Dean","year":"2012","unstructured":"Dean L. Warfarin Therapy and VKORC1 and CYP genotype. Medical Genetics Summaries. MD: National Center for Biotechnology Information (US); 2012."},{"key":"6359_CR4","first-page":"546","volume":"138","author":"MB Pagano","year":"2012","unstructured":"Pagano MB, Chandler WL. Bleeding risks and response to therapy in patients with INR higher than 9. American journal of clinical pathology. England. 2012;138:546\u201350.","journal-title":"England"},{"key":"6359_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000481207","volume":"46","author":"MC Lin","year":"2017","unstructured":"Lin MC, Streja E, Soohoo M, Hanna M, Savoj J, Kalantar-Zadeh K, et al. Warfarin Use and increased mortality in end-stage renal disease. Am J Nephrol. 2017;46:249\u201356.","journal-title":"Am J Nephrol"},{"key":"6359_CR6","volume-title":"Health Systems in Transition","author":"S Thinley","year":"2017","unstructured":"Thinley S, Tshering P, Wangmo K, Wangchuk N, Dorji T, Tobgay T et al. The Kingdom of Bhutan Health System Review. Health Systems in Transition. New Delhi, India: World Health Organization. Regional Office for South-East Asia; 2017."},{"key":"6359_CR7","unstructured":"Ministry of Health. National Essential Medicines List. 2021. Thimphu: Ministry of Health, Royal Government of Bhutan; 2021."},{"key":"6359_CR8","unstructured":"Jigme Dorji Wangchuck National Referral Hospital. Annual Report 2021. Thimphu: Jigme Dorji Wangchuck National Referral Hospital; 2021."},{"key":"6359_CR9","volume-title":"Annual Report 2018","author":"Jigme Dorji Wangchuck National Referral Hospital","year":"2018","unstructured":"Jigme Dorji Wangchuck National Referral Hospital. Annual Report 2018. Thimphu: Jigme Dorji Wangchuck National Referral Hospital; 2018."},{"key":"6359_CR10","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","volume":"8","author":"F Rodeghiero","year":"2010","unstructured":"Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemostasis Engl. 2010;8:2063\u20135.","journal-title":"J Thromb Haemostasis Engl"},{"key":"6359_CR11","unstructured":"Ministry of Health. National essential Medicines List 2016. Ministry of Health, Royal Government of Bhutan; 2016."},{"key":"6359_CR12","first-page":"22","volume":"3","author":"H Nekkanti","year":"2012","unstructured":"Nekkanti H, Mateti UV, Vilakkathala R, Rajakannan T, Mallayasamy S, Padmakumar R. Predictors of warfarin-induced bleeding in a south indian cardiology unit. Perspectives in Clinical Research. India. 2012;3:22\u20135.","journal-title":"India"},{"key":"6359_CR13","doi-asserted-by":"publisher","unstructured":"Chen A, Stecker E, Warden BA. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. Journal of the American Heart Association [Internet]. 2020;9:e017559. Available from: https:\/\/www.ahajournals.org\/doi\/abs\/https:\/\/doi.org\/10.1161\/JAHA.120.017559.","DOI":"10.1161\/JAHA.120.017559"},{"key":"6359_CR14","doi-asserted-by":"crossref","unstructured":"Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmunity reviews. Netherlands; 2021;20:102711.","DOI":"10.1016\/j.autrev.2020.102711"},{"key":"6359_CR15","unstructured":"National Statistics Bureau of Bhutan. 2017 Population & Housing Census of Bhutan - National Report. Thimphu; 2018."},{"key":"6359_CR16","doi-asserted-by":"publisher","unstructured":"Shrestha S, Sapkota B, Kumpakha A, Acharya U, Sharma R. Evaluation of patients\u2019 knowledge on warfarin in outpatient pharmacy of a tertiary care cardiac center. BMC Research Notes [Internet]. 2015;8:429. Available from: https:\/\/doi.org\/10.1186\/s13104-015-1416-1.","DOI":"10.1186\/s13104-015-1416-1"},{"key":"6359_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12875-019-1041-5","volume":"20","author":"LBE Shields","year":"2019","unstructured":"Shields LBE, Fowler P, Siemens DM, Lorenz DJ, Wilson KC, Hester ST, et al. Standardized warfarin monitoring decreases adverse drug reactions. BMC Fam Pract. 2019;20:151.","journal-title":"BMC Fam Pract"},{"key":"6359_CR18","doi-asserted-by":"publisher","unstructured":"Iqbal MS, Muthanna FMS, Kassab YW, Hassali MA, Al-Saikhan FI, Iqbal MZ et al. Determinants of health-related quality of life among warfarin patients in Pakistan. PLOS ONE [Internet]. Public Library of Science; 2020;15:1\u201316. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0234734.","DOI":"10.1371\/journal.pone.0234734"},{"key":"6359_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","volume":"144","author":"S Apostolakis","year":"2013","unstructured":"Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest United States. 2013;144:1555\u201363.","journal-title":"Chest United States"},{"key":"6359_CR20","doi-asserted-by":"publisher","unstructured":"Lertsanguansinchai P, Huntrakul A, Rungpradubvong V, Chokesuwattanaskul R, Prechawat S. Factors predicting poor anticoagulant control on warfarin in a Thai population with non-valvular atrial fibrillation (NVAF): the ACAChE score. International Journal of Arrhythmia [Internet]. 2021;22:9. Available from: https:\/\/doi.org\/10.1186\/s42444-021-00038-8.","DOI":"10.1186\/s42444-021-00038-8"},{"key":"6359_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ihj.2021.02.003","volume":"73","author":"V Ramakumar","year":"2021","unstructured":"Ramakumar V, Benz AP, Karthikeyan G. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries. Indian Heart Journal India. 2021;73:244\u20138.","journal-title":"Indian Heart Journal India"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06359-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T11:06:18Z","timestamp":1684407978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6359"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06359-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"10 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Research Ethics Board of Health, Ministry of Health, Bhutan (approval no REBH\/Approval\/2020\/059 dated 28\/09\/2020). The need for informed consent was waived by the Research Ethics Board of Health, Ministry of Health, Thimphu, Bhutan because this was a review of hospital records and not patient identifiers were collected. Consent to participate is not applicable as no patients were involved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"81"}}